|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHRS4 |
Gene summary for DHRS4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHRS4 | Gene ID | 10901 |
| Gene name | dehydrogenase/reductase 4 | |
| Gene Alias | CR | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0001523 | UniProtAcc | Q9BTZ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10901 | DHRS4 | LZE5T | Human | Esophagus | ESCC | 4.68e-05 | 3.27e-01 | 0.0514 |
| 10901 | DHRS4 | LZE7T | Human | Esophagus | ESCC | 5.57e-09 | 3.79e-01 | 0.0667 |
| 10901 | DHRS4 | LZE8T | Human | Esophagus | ESCC | 8.75e-16 | 5.41e-01 | 0.067 |
| 10901 | DHRS4 | LZE22T | Human | Esophagus | ESCC | 9.95e-04 | 5.94e-01 | 0.068 |
| 10901 | DHRS4 | LZE24T | Human | Esophagus | ESCC | 2.33e-27 | 6.34e-01 | 0.0596 |
| 10901 | DHRS4 | LZE21T | Human | Esophagus | ESCC | 4.13e-05 | 3.73e-01 | 0.0655 |
| 10901 | DHRS4 | LZE6T | Human | Esophagus | ESCC | 1.54e-07 | 5.31e-01 | 0.0845 |
| 10901 | DHRS4 | P1T-E | Human | Esophagus | ESCC | 2.60e-05 | 2.78e-01 | 0.0875 |
| 10901 | DHRS4 | P2T-E | Human | Esophagus | ESCC | 2.57e-42 | 7.55e-01 | 0.1177 |
| 10901 | DHRS4 | P4T-E | Human | Esophagus | ESCC | 1.30e-47 | 1.07e+00 | 0.1323 |
| 10901 | DHRS4 | P5T-E | Human | Esophagus | ESCC | 5.18e-19 | 5.09e-01 | 0.1327 |
| 10901 | DHRS4 | P8T-E | Human | Esophagus | ESCC | 2.05e-26 | 5.43e-01 | 0.0889 |
| 10901 | DHRS4 | P9T-E | Human | Esophagus | ESCC | 3.86e-34 | 6.80e-01 | 0.1131 |
| 10901 | DHRS4 | P10T-E | Human | Esophagus | ESCC | 7.31e-64 | 1.03e+00 | 0.116 |
| 10901 | DHRS4 | P11T-E | Human | Esophagus | ESCC | 1.05e-32 | 1.06e+00 | 0.1426 |
| 10901 | DHRS4 | P12T-E | Human | Esophagus | ESCC | 1.57e-76 | 1.47e+00 | 0.1122 |
| 10901 | DHRS4 | P15T-E | Human | Esophagus | ESCC | 1.22e-69 | 1.36e+00 | 0.1149 |
| 10901 | DHRS4 | P16T-E | Human | Esophagus | ESCC | 3.33e-39 | 7.65e-01 | 0.1153 |
| 10901 | DHRS4 | P17T-E | Human | Esophagus | ESCC | 3.35e-20 | 6.68e-01 | 0.1278 |
| 10901 | DHRS4 | P19T-E | Human | Esophagus | ESCC | 5.18e-22 | 1.06e+00 | 0.1662 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006066 | Colorectum | AD | alcohol metabolic process | 106/3918 | 353/18723 | 3.02e-05 | 5.57e-04 | 106 |
| GO:0072593 | Colorectum | AD | reactive oxygen species metabolic process | 73/3918 | 239/18723 | 2.79e-04 | 3.42e-03 | 73 |
| GO:2000379 | Colorectum | AD | positive regulation of reactive oxygen species metabolic process | 29/3918 | 76/18723 | 4.31e-04 | 4.82e-03 | 29 |
| GO:0034308 | Colorectum | AD | primary alcohol metabolic process | 35/3918 | 102/18723 | 1.16e-03 | 1.05e-02 | 35 |
| GO:2000377 | Colorectum | AD | regulation of reactive oxygen species metabolic process | 48/3918 | 157/18723 | 2.77e-03 | 2.09e-02 | 48 |
| GO:0008202 | Colorectum | AD | steroid metabolic process | 85/3918 | 319/18723 | 8.07e-03 | 4.75e-02 | 85 |
| GO:00725931 | Colorectum | SER | reactive oxygen species metabolic process | 61/2897 | 239/18723 | 3.63e-05 | 9.39e-04 | 61 |
| GO:20003791 | Colorectum | SER | positive regulation of reactive oxygen species metabolic process | 24/2897 | 76/18723 | 3.29e-04 | 5.22e-03 | 24 |
| GO:00060661 | Colorectum | SER | alcohol metabolic process | 79/2897 | 353/18723 | 3.50e-04 | 5.50e-03 | 79 |
| GO:20003771 | Colorectum | SER | regulation of reactive oxygen species metabolic process | 41/2897 | 157/18723 | 3.86e-04 | 5.86e-03 | 41 |
| GO:00343081 | Colorectum | SER | primary alcohol metabolic process | 26/2897 | 102/18723 | 5.87e-03 | 4.29e-02 | 26 |
| GO:00060662 | Colorectum | MSS | alcohol metabolic process | 92/3467 | 353/18723 | 2.57e-04 | 3.46e-03 | 92 |
| GO:20003792 | Colorectum | MSS | positive regulation of reactive oxygen species metabolic process | 25/3467 | 76/18723 | 1.91e-03 | 1.66e-02 | 25 |
| GO:00725932 | Colorectum | MSS | reactive oxygen species metabolic process | 62/3467 | 239/18723 | 2.68e-03 | 2.12e-02 | 62 |
| GO:20003772 | Colorectum | MSS | regulation of reactive oxygen species metabolic process | 42/3467 | 157/18723 | 6.83e-03 | 4.40e-02 | 42 |
| GO:200037718 | Esophagus | ESCC | regulation of reactive oxygen species metabolic process | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
| GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
| GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
| GO:200037918 | Esophagus | ESCC | positive regulation of reactive oxygen species metabolic process | 45/8552 | 76/18723 | 1.21e-02 | 4.04e-02 | 45 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa041462 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041463 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041466 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414611 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414621 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| hsa0414631 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHRS4 | SNV | Missense_Mutation | c.289N>A | p.Glu97Lys | p.E97K | Q9BTZ2 | protein_coding | tolerated(0.55) | benign(0.006) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| DHRS4 | insertion | Nonsense_Mutation | novel | c.211_212insGTCCTCCCTTTTATCCATCCACCCATCCATTCATTTGCT | p.Gln71delinsArgProProPheTyrProSerThrHisProPheIleCysTer | p.Q71delinsRPPFYPSTHPFIC* | Q9BTZ2 | protein_coding | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| DHRS4 | SNV | Missense_Mutation | rs200717541 | c.344N>G | p.Ser115Cys | p.S115C | Q9BTZ2 | protein_coding | tolerated(0.43) | benign(0.063) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHRS4 | SNV | Missense_Mutation | novel | c.829N>T | p.Arg277Cys | p.R277C | Q9BTZ2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| DHRS4 | SNV | Missense_Mutation | novel | c.203N>T | p.Asn68Ile | p.N68I | Q9BTZ2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| DHRS4 | SNV | Missense_Mutation | rs754460638 | c.746N>T | p.Ala249Val | p.A249V | Q9BTZ2 | protein_coding | deleterious(0.01) | benign(0.339) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| DHRS4 | SNV | Missense_Mutation | novel | c.611N>G | p.Asn204Ser | p.N204S | Q9BTZ2 | protein_coding | deleterious(0.03) | benign(0.313) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| DHRS4 | SNV | Missense_Mutation | c.644N>G | p.Ile215Ser | p.I215S | Q9BTZ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-A1EA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| DHRS4 | SNV | Missense_Mutation | rs761725199 | c.299N>G | p.Val100Gly | p.V100G | Q9BTZ2 | protein_coding | deleterious(0.01) | benign(0.384) | TCGA-DD-A3A7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | PD |
| DHRS4 | SNV | Missense_Mutation | novel | c.344N>T | p.Ser115Phe | p.S115F | Q9BTZ2 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-85-A4JC-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |